NIH R01 · 2025
Therapeutic targeting mesenchymal transition in newly diagnosed and recurrent GBM
PROJECT SUMMARY IDHwt glioblastoma (GBM) patients still live an average of ~15-months, despite advances in multimodal therapy. A central issue confounding treatment is the heterogeneous nature of this aggressive tumor. Transcriptomics has defined three GBM molecular subtypes - proneural (PN), classical (CL), and mesenchymal (MES).7 Individual tumors typically harbor mixtures of all three subtypes in spatially distinct subpopulations with different mutation profiles, making mutation- or pathway-specific therapies less effective. While cell-intrinsic mechanisms of therapeutic resistance have garnered considerable scientific attention, much less is known about cellular interactions in the…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.